Navigation Links
Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Date:6/24/2008

IRVINE, Calif., June 24 /PRNewswire/ -- Stason Pharmaceuticals, Inc., a vertically integrated cGMP contract development organization announced today that it has appointed Diana Wood as Vice President, Business Development. Ms. Wood will be responsible for all business development functions, including guiding Stason's global business development activities. Ms. Wood is a senior executive with extensive experience in sales, marketing, business and strategic planning, product development and general management on a worldwide basis. She will report directly to Chief Executive Officer Harry T. Fan. Most recently, Diana Wood served as the Executive Vice President, Business Development at Chiltern International, Inc., where she oversaw the company's global business development and marketing functions, and advised clients on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at Chugai Pharma USA in San Diego.

"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a highly respected track record and earned the trust of the pharmaceutical community. Diana will be a strategically important asset to our company. Furthermore, by bringing an extensive knowledge of the pharmaceutical industry and its regulatory environment combined with confidence and multifaceted business experience, she will continue to broaden and strengthen our relationship with our drug development partners."

"I am delighted to join Stason, a fast-growing and forward thinking organization," Ms. Wood said. "Today's product development landscape is changing rapidly and paradigms are shifting towards a more technologically driven development process from the bench to market. Stason embraced these changes early on, reducing overall development time and costs. I look forward to bringing new opportunities to Stason and to further expand our global growth."

About Stason Pharmaceuticals:

Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.


'/>"/>
SOURCE Stason Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
2. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
3. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
4. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Medimetriks Pharmaceuticals, Inc. Begins Operations
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
10. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
11. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):